Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1990 4
1991 2
1992 7
1993 10
1994 7
1995 14
1996 7
1997 13
1998 14
1999 12
2000 6
2001 26
2002 18
2003 16
2004 16
2005 15
2006 13
2007 16
2008 7
2009 2
2010 12
2011 15
2012 9
2013 15
2014 11
2015 17
2016 17
2017 7
2018 15
2019 9
2020 12
2021 20
2022 9
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

388 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab (Keytruda).
Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Kwok G, et al. Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789. doi: 10.1080/21645515.2016.1199310. Epub 2016 Jul 11. Hum Vaccin Immunother. 2016. PMID: 27398650 Free PMC article. Review.
The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. ...It was superior to another immune checkpoint inhibitor ipilimumab (Yervoy) in stage III/IV unresectable melanoma. In refractory non-small
The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. ...It was superior to another …
Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.
Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Chaft JE, et al. Nat Rev Clin Oncol. 2021 Sep;18(9):547-557. doi: 10.1038/s41571-021-00501-4. Epub 2021 Apr 28. Nat Rev Clin Oncol. 2021. PMID: 33911215 Free PMC article. Review.
In 2018, the anti-PD-L1 antibody durvalumab was approved for patients with stage III lung cancer after concurrent chemoradiotherapy. Since then, the study of targeted therapies and immunotherapies in patients with early-stage lung cancer
In 2018, the anti-PD-L1 antibody durvalumab was approved for patients with stage III lung cancer after concurrent chemo …
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.
Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F. Dantoing E, et al. Int J Mol Sci. 2021 Jun 11;22(12):6288. doi: 10.3390/ijms22126288. Int J Mol Sci. 2021. PMID: 34208111 Free PMC article. Review.
Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung cancer (NSCLC) over the past decade. ...
Anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for stage III-IV non-small cell lung
Lung Cancer Staging and Prognosis.
Woodard GA, Jones KD, Jablons DM. Woodard GA, et al. Cancer Treat Res. 2016;170:47-75. doi: 10.1007/978-3-319-40389-2_3. Cancer Treat Res. 2016. PMID: 27535389 Review.
The seventh edition of the non-small cell lung cancer (NSCLC) TNM staging system was developed by the International Association for the Staging of Lung Cancer (IASLC) Lung Cancer Staging Project b …
The seventh edition of the non-small cell lung cancer (NSCLC) TNM staging system was developed by …
Progress and prospects of early detection in lung cancer.
Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Blandin Knight S, et al. Open Biol. 2017 Sep;7(9):170070. doi: 10.1098/rsob.170070. Open Biol. 2017. PMID: 28878044 Free PMC article. Review.
It is broadly divided into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx. 85% cases). ...However, most patients (approx. 75%) have advanced disease at the time of diagnosis (stage III/ …
It is broadly divided into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer
Acquired resistance mechanisms to osimertinib: The constant battle.
Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, Planchard D. Zalaquett Z, et al. Cancer Treat Rev. 2023 May;116:102557. doi: 10.1016/j.ctrv.2023.102557. Epub 2023 Apr 7. Cancer Treat Rev. 2023. PMID: 37060646 Review.
Lung cancer is the leading cause of cancer-related mortality worldwide. ...Osimertinib (AZD9291) is an irreversible third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used to treat stage IV EGFR-mutated non
Lung cancer is the leading cause of cancer-related mortality worldwide. ...Osimertinib (AZD9291) is an irreversible thi
Lung Cancer: Management.
Mott TF. Mott TF. FP Essent. 2018 Jan;464:27-30. FP Essent. 2018. PMID: 29313655 Review.
Lung cancer management that is individualized for age, comorbidities, cancer type, cancer stage, and patient preference has long been a cornerstone of management. New to this realm of individualized management are the emerging biologic therapies
Lung cancer management that is individualized for age, comorbidities, cancer type, cancer stage, and pati
Challenges of Immunotherapy in Stage IV Non-Small-Cell Lung Cancer.
Stock-Martineau S, Magner K, Jao K, Wheatley-Price P. Stock-Martineau S, et al. JCO Oncol Pract. 2021 Aug;17(8):465-471. doi: 10.1200/OP.20.00949. Epub 2021 Mar 15. JCO Oncol Pract. 2021. PMID: 33720756 Review.
Treatment for metastatic non-small-cell lung carcinoma has seen important advances in recent years with the introduction of targeted therapies and immunotherapy. Immune checkpoint inhibitors, which target the programmed death 1 receptor and prog …
Treatment for metastatic non-small-cell lung carcinoma has seen important advances in recent years with t …
Treatment options in stage III non-small cell lung cancer.
Paraschiv B, Diaconu CC, Dumitrache-Rujinski S, Belaconi IN, Constantinescu T, Stroescu CC, Dantes E, Fildan AP, Bogdan MA, Toma CL. Paraschiv B, et al. Pneumologia. 2016 Apr-Jun;65(2):67-70. Pneumologia. 2016. PMID: 29538961 Review.
Lung cancer is responsible for over 1 million deaths annually, worldwide. ...In NSCLC surgical resection represents the best option for long term survival in resectable stage III and in clinical stage I/II. Patients with stage IIIB or IV
Lung cancer is responsible for over 1 million deaths annually, worldwide. ...In NSCLC surgical resection represents the best o
Extending survival of stage IV non-small cell lung cancer.
Carnio S, Novello S, Mele T, Levra MG, Scagliotti GV. Carnio S, et al. Semin Oncol. 2014 Feb;41(1):69-92. doi: 10.1053/j.seminoncol.2013.12.013. Epub 2013 Dec 21. Semin Oncol. 2014. PMID: 24565582 Free article. Review.
Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with locally advanced or metastatic disease. ...Currently no agents are specifically approved for the treatment of squamous cell carcinoma of the l
Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with locally advanced or …
388 results